In systemic lupus erythematosus (SLE), peripheral neuropathies are relatively uncommon and rarely present as the initial symptom. Weherein describe a 61-year-old womanwho developed a sudden onset of drop foot, which was indistinguishable from Guillain-Barre syndrome based on the clinical symptoms alone. Antibodies against ganglioside GM1were detected in the serum, while no antibodies to Campylobacterjejuni were observed. Anelectrophysiological study showed axonal impairment rather than demyelination. A pathological examination of a sural nerve biopsy specimen and further laboratory examinations suggested the observed peripheral neuropathies to have arisen due to lupus vasculitis. The serological activities of SLEresponded well to treatment with corticosteroids, mizoribine and immunoadsorption therapies, however, the drop foot symptoms did not change remarkably. (Internal Medicine 38: 729-732, 1999) 
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multiple organ involvement. Although a central nervous system manifestation has been regarded as one of the main abnormalities of this disease, peripheral neuropathies are relatively uncommon ( 1 ) . Peripheral neuropathies in SLEmay include sensory, motor, mixed sensorimotor polyneuropathy or multiple mononeuropathy. In addition, acute demyelinating polyneuropathy of Guillain-Barre type and chronic inflammatory demyelinating polyneuropathy have also been reported (1) . Multiple mononeuropathy is mainly caused by neural ischemia due to the inflammation of epineural arterioles and usually develops as a late complication of SLE (2, 3) .
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onal degeneration and also a poor recovery in GBS (5) . These antibodies are also detected in rheumatic diseases, such as SLE and rheumatoid arthritis, either with or without neuropathies (6, 7) . Here, we report a patient with SLE who presented with multiple mononeuropathy as the initial symptomand also demonstrated an increased titer of serum anti-GMl.
Case Report
A 61-year-old Japanese womanwas admitted for symptoms of left drop foot with an acute onset and hypesthesia in her lower distal extremities. A month prior to admission, she experienced a sore throat and arthralgia in her knees and shoulders. She had no history of diabetes mellitus, nerve trauma, alcoholism, drug addiction, recent immunization, or exposure to either toxic metals or industrial agents. There was also no family history of any hereditary neuropathies.
Uponadmission, her consciousness was clear and a physical examination of the patient yielded the following data: temperature, 37.4°C; blood pressure, 124/70 mmHgmeasured at each arm; pulse regular at 96 beats/min. A neurological test showed an inability to flex her left foot dorsally, along with hypesthesia of the distal extremities in a stocking-and-glove distribution, and the disappearance of the deep tendon reflexes at the knees and ankles. There were also no abnormal findings in the cranial and autonomic nerves. In addition, neither muscular fasciculation nor swollen joints were recognized. The erythrocyte sedimentation rate was 5 1 mm/h. The findings of both a urinalysis and a stool examination were unremarkable. Blood examinations revealed the following data: leukocyte count, 4, 100/|jl (neutrophils, 78.9%; lymphocytes, 18.9); erythrocyte count, 382xlO4/jal; hemoglobin, 10.7 g/dl; hematocrit, 32.9%; platelet count, 17.7x lO4/|al. Chemical analyses of the serumand clotting were within the normal limits.
Microbiological assessments were negative, including blood cultures and serology for hepatitis B virus (HBV), hepatitis C virus (HCV), and C. jejuni. The level of serum anti-GMl immunoglobulin G (IgG) was 3,530 U (enzyme-linked immunosorbent assay; ELISA, normal < 800 U), and the antiGMl immunoglobulin M (IgM) was lower than 800 U (ELISA, normal < 800 U) upon admission. The results of a cerebrospinal fluid analysis were as follows: cell count, 7/3; total protein, 57 mg/dl; IgG, 12.2 (normal, < 5.0); glucose, 50. An electrophysiological test revealed the compoundmuscle action potential in the left peroneal nerve to not be evoked; the amplitudes of the action potentials in the right peroneal and bilateral posterior tibial nerves decreased to less than 25% of the lower cut-off level of the normal range, while the conduction velocities of these nerves were all within the normal limits; no Fwave was detected; no certain abnormality of the nerve conduction was detected in the upper limb. These results thus suggested that the neural impairments arose from axonal degeneration, rather than from demyelination which is commonly recognized in GBS. Wetherefore, attempted to identify the cause(s) of these peripheral polyneuropathies, including the possibility that vasculitis could be the cause. Further findings of the immunological studies were as follows: C-reactive protein, 2.2 mg/dl; IgG, 2,689; IgA, 344; IgM, 176; C3 22; C4, 9; CH50, 1 1.0 U/ml; cryoglobulin, positive; antinuclear antibody, 1: 20,480 (homogeneous pattern);
anti-dsDNA, 207 IU/ml (ELISA); high-avidity anti-DNA antibodies (8), 47.0%; anti-SS-A, positive (immunoprecipitation); anti-SS-B, 1 :2 (double immunodiffusion); anti-Sm, negative, P and C anti-neutrophil cytoplasmic antibodies, both negative. A histopathological examination of the left sural nerve biopsy specimen showed vasculitis of the small vessels ( Fig. 1) and axonal swelling.
Echocardiogram showed a small amount of pericardial effusion around the lateral and posterior left ventricular wall. A diagnosis of SLE was made because she had 6 items (arthritis, After admission and within 2 weeks after the onset of drop foot, treatment was started with double filtration plasmapheresis (10), because GBSwas highly suspected to be the cause of the neuropathies. After the diagnosis of lupus vasculitis was made (one month after admission), the treatment was changed to methylprednisolone (40 mg/day), mizoribine ( 150 mg/day, ref. 1 1) and two sessions of immunoadsorption (8) . These therapies improved the arthralgia, the serological activities, and the SLEDAI score (12) decreased from 18 points to 6 points during the 3-month hospitalization period. Nevertheless, the foot drop, the hypesthesia of the lower extremities, and the electrophysiological findings did not change substantially during the admission. About 2 months after discharge, the foot drop was gradually improved by medication and rehabilitation. Six months after discharge, an electrophysiological test revealed that the amplitudes of the action potentials in the right peroneal and bilateral posterior tibial nerves recovered to the level of more than 50%of the lower cut-off of the normal range. Sixteen months after discharge, the level of serum anti-GMl IgG decreased to the normal range (< 800 U, ELISA).
Discussion
The involvement of the central nervous system is one of the major clinical features in SLE and is recognized in 24-51% of all cases (13), whereas the incidence of peripheral neuropathy is relatively low, ranging from 10-21% (1). However, as the initial symptomof SLE, peripheral neuropathies have rarely been described ( Table 1) . As listed in the Table 1 , various peripheral neuropathies, such as acute or chronic demyelinating polyneuropathy, multiple mononeuropathy, symmetrical distal sensorimotor neuropathy, were recognized. The diagnosis of peripheral neuropathies associated with SLEcan be confusing, especially in the early phase of this disease. After admission, the present patient fulfilled some diagnostic criteria for GBS (4), including progressive weakness of the legs, areflexia, and a slight elevation of protein level without leukocytosis in the cerebrospinal fluid. However, the results of an electrophysiological test were inconsistent with typical GBS, but did indicate the peripheral neuropathies to be due to axonal degeneration. Further studies revealed the presence of antinuclear and anti-DNAantibodies, as well as pathological evidence of vasculitis. These findings thus represent conclusive evidence that the patient had SLE. Peripheral neuropathy develops as one of the neurological manifestations of Sjogren's syndrome, cryoglobulinemia, and antiphospholipid syndrome (APS), as well as SLE (2, 24) . Both serum anti-SS-B and cryoglobulin were detected in this patient, however,no symptoms of sicca or purpura were recognized. In addition, no clinical features ofAPS, such as a history of habitual abortion, thrombocytopenia, a prolonged activated partial thromboplastin time or pathological proof of thrombosis were observed in the present case. Anti-GMl is significantly associated with GBS (5) and is also elevate'd in the serum of such rheumatic disorders, as SLE (6) . The mechanisms of action of anti-GMl are still unclear, however it seems that the antibodies directed against gangliosides of the neural membranesmight exert a pathophysiologic effect, such as a conduction block, via complementactivation (4). The subgroup of GBSpatients with anti-GMl has been found to be associated with axonal impairment, as well as rap- idly progressive and severe neuropathy (5) . Considering the findings of an electrophysiological study and the refractory neurological symptomsof this patient, anti-GMl might have played a role in the pathogenesis of the present case. Hirano et al (7) revealed the fluctuation in the anti-GMl titers to be related to the occurrence of seizures in SLE patients. The present patient had no history of seizures. The correlation between the presence of serum anti-GM1 and the development of peripheral neuropathy still remains controversial in collagen diseases (6) .
In some SLEcases, peripheral neuropathies responded to corticosteroid therapy combined with various treatments, such as plasma exchange, azathioprine, oral or pulse intravenous cyclophosphamide, adrenocorticotropic hormone (Table 1 ) , or intravenous prostaglandin El (24) . In the cases listed in Table  1 , improvementsof the neurological symptoms were obtained in 1 week to 6 months after the beginning of the treatment. The period required for the amelioration of neurological symptoms in the present patient was 4 months. In this case, oral corticosteroids, an immunosuppressant,and immunoadsorptionwere administered roughly 1 month after the onset of drop foot. Before the diagnosis of SLEwas made, we performed double filtration plasmapheresis without steroids and/or immunosuppressive agents. The performance of plasmapheresis without administering any drugs, which is accepted as a typical therapy for GBS (10) , might thus have contributed to the rebound autoantibody production in SLE (25) . The retarded institution of the immunosuppressive therapy and/or the rebound autoantibody production by the plasmapheresis might have been related to the comparatively delayed amelioration of the foot drop in this case.
